Small molecule targeting FOXM1 DNA binding domain exhibits anti-tumor activity in ovarian cancer

• DOI: 10.1038/s41420-022-01070-w
• Publication Date: 2022-06-09T09:14:05Z
• Authors: Zaixin Zhang; Si-tu Xue; Yan Gao; Yingwei Li; Ziying Zhou; Jing Wang; Zhuorong Li; Zhaojian Liu
• Keywords: FOXM1

FOXM1 is a potent oncogenic transcription factor essential for cancer initiation, progression, and drug resistance. regulatory network major predictor of adverse outcomes in various human cancers. Inhibition function potential strategy treatment. In this study, we performed structure-based silico screening to discover small molecules targeting the DNA-binding domain (DBD). Compound XST-20 was identified effectively suppress transcriptional activities inhibit ovarian cell proliferation. directly interacts with determined by SPR assay. Furthermore, found significantly reduce colony-forming efficiency induce cycle arrest apoptosis. Our study provides lead compound inhibitor which may serve as targeted therapy agent cancer.